Immuneering - Class A (IMRX) closed at $3.81 on October 22, 2026, up 1.9% from the previous close, on volume of 517,766 shares (30-day average 689,627).
Data as of October 22, 2026.
Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Globe Newswire (Fri, 2-Oct 9:00 AM ET)
Globe Newswire (Mon, 28-Sep 7:30 AM ET)
Immuneering to Present at the ESMO Congress 2026
Globe Newswire (Thu, 24-Sep 7:30 AM ET)
Globe Newswire (Thu, 10-Sep 7:30 AM ET)
Immuneering to Participate in Upcoming Investor Conferences
Globe Newswire (Thu, 3-Sep 4:05 PM ET)
Globe Newswire (Wed, 26-Aug 5:16 PM ET)
Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates
Globe Newswire (Wed, 5-Aug 7:30 AM ET)
Market Chameleon (Fri, 22-May 6:30 AM ET)
Market Chameleon (Fri, 22-May 3:29 AM ET)
Market Chameleon (Mon, 29-Sep 3:41 AM ET)
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Immuneering - Class A trades on the NASDAQ stock market under the symbol IMRX.
As of October 23, 2026, IMRX stock price declined to $3.68 with 461,103 million shares trading.
IMRX has a beta of 0.93, meaning it tends to be less sensitive to market movements. IMRX has a correlation of 0.03 to the broad based SPY ETF.
IMRX has a market cap of $237.92 million. This is considered a Small Cap stock.
In the last 3 years, IMRX traded as high as $10.08 and as low as $1.00.
The top ETF exchange traded funds that IMRX belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.
IMRX has underperformed the market in the last year with a return of -31.2%, while the SPY ETF gained +15.1%. In the last 3 month period, IMRX fell short of the market, returning -17.7%, while SPY returned +2.0%. However, in the most recent 2 weeks IMRX has outperformed the stock market by returning -1.6%, while SPY returned -1.7%.
IMRX support price is $3.68 and resistance is $3.94 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMRX shares will trade within this expected range on the day.
